DBV Technologies S.A. (DBVT) 株式分析

企業概要

DBV Technologies S.A. is a clinical-stage biopharmaceutical entity focused on the research and development of epicutaneous immunotherapy products within the French market, primarily advancing Viaskin Peanut for the treatment of peanut allergies. The company operates in the Healthcare sector, specifically within the Biotechnology industry, which implies a high degree of scientific complexity and reliance on successful clinical trial outcomes before commercial viability is achieved. As of the latest data, DBV Technologies holds a market capitalization of $1.27B and reports a trailing twelve-month revenue of $5.64M, though specific employee count data is not publicly disclosed in the provided records. The combination of a $1.27B market cap with annual revenues of only $5.64M indicates that the company is valued significantly on future growth potential and pipeline assets rather than current cash flow generation, positioning it as a capital-intensive venture typical of early-stage biotech firms where valuation is decoupled from immediate profitability.

財務健全性

The company reported a trailing twelve-month revenue of $5.64M, yet this figure masks a substantial deficit in net income of $-146,947,008 and an EBITDA of $-143,862,000. The widening gap between the modest revenue of $5.64M and the massive net loss of approximately $147M reveals a cost structure dominated by heavy research and development expenditures and clinical trial costs that far exceed current sales. Additionally, the free cash flow stands at $-64,285,000, indicating that the company is burning cash at a rapid pace, which necessitates a continuous influx of external capital to maintain operations and advance its product pipeline. Analysis of the three key margins shows a Gross Margin of 100.0%, suggesting no cost of goods sold against current sales, contrasted sharply by an Operating Margin of -6984.7% and a Profit Margin of 0.0%, both reflecting extreme operational inefficiency relative to current sales volume due to the scale of losses. Regarding balance sheet strength, the firm holds $194.17M in cash against total debt of $6.53M, resulting in a Debt to Equity ratio of 3.87, which presents a complex picture of high leverage relative to equity while simultaneously possessing ample liquidity to service its minimal debt obligations. The Current Ratio is reported at 3.67, indicating that the company possesses more than three times the current assets necessary to cover its short-term liabilities, suggesting strong short-term liquidity despite the operational losses. Furthermore, the Return on Equity is -149.8% and the Return on Assets is -61.4%, metrics that reveal that management has not yet generated positive returns on the capital invested, a common characteristic for clinical-stage companies still in the investment phase of their lifecycle.

バリュエーション評価

DBV Technologies exhibits a Forward P/E of -81.03, while the Trailing P/E is N/A due to the lack of positive earnings, implying that traditional price-to-earnings valuation models are currently inapplicable. The Price to Book ratio stands at 5.98, indicating that the market values the company at nearly six times its book value, a significant premium that reflects the high valuation placed on its intangible assets and potential future commercial success. Alternative valuation metrics such as the Price to Sales ratio of 224.72 and an EV/EBITDA of -33.74 suggest that investors are pricing the stock based on theoretical future sales multiples rather than current financial performance. In terms of trading range, the 52-week high is $26.18 and the 52-week low is $6.69; without a specific current price provided in the source data, the valuation context relies on these historical bounds to define the potential volatility range. The Beta is -0.20, a unique and anomalous statistic for an equity security, which technically implies an inverse relationship with the broader market or a data anomaly, but strictly stated, it suggests price movements that do not correlate positively with standard market indices.

Growth & Income

The company demonstrates robust revenue growth with a Year-over-Year increase of 26.2%, whereas earnings growth is N/A due to the absence of profitability. Since earnings growth is not applicable in a negative earnings environment, the divergence between rising revenue and deepening losses implies that top-line expansion is not yet translating into bottom-line gains, a typical dynamic for companies scaling their clinical operations. As a non-dividend payer, DBV Technologies reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, confirming that the company retains all available cash to fund its research and development rather than distributing income to shareholders. This reinvestment strategy aligns with the business model of a clinical-stage biopharmaceutical firm where capital preservation is prioritized to sustain long-term growth prospects. The overall growth and income profile is characterized by accelerating sales revenue coupled with significant cash consumption, resulting in a zero-dividend status and a valuation driven entirely by future commercialization potential rather than current income generation or historical profitability.